| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Veterinary Science, The University of Melbourne, Victoria 3010, Australia
2 Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, The Royal Melbourne Hospital, Victoria 3050, Australia
Correspondence
Glenn F. Browning
glenfb{at}unimelb.edu.au
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
The GenBank/EMBL/DDBJ accession number for the nucleotide sequence reported in this paper is AF227982.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). CAV infection is ubiquitous in poultry flocks worldwide and significant production losses can occur as a consequence of both clinical and subclinical infections of commercial poultry (Fadley et al., 1994; Farkas et al., 1996; McNulty et al., 1988, 1989; von Bulow & Lesjak, 1987; Yuasa, 1983; Yuasa et al., 1983). Infections are of increasing concern because of their role in vaccination failure, reduced production performance and potentiation of other infectious diseases, including Marek's disease (Barbour et al., 2002; Bisgaard, 1983; Caterina et al., 2004; Chettle et al., 1988; Engstrom et al., 1988; Markowski-Grimsrud & Schat, 2003; McIlroy et al., 1992; McNulty, 1997; McNulty et al., 1988; Miller & Schat, 2004; Sommer & Cardona, 2003; Vielitz & Landgraf, 1988). In addition, as the CAV viral protein 2 (VP2) protein has functional homology to the homologous ORF2 of the group of viruses known collectively as TT viruses (TTV), CAV could be a model for investigations of these viruses, which have been detected in a high proportion of humans, but which are not cultivable and are of uncertain pathogenic significance.
CAV encodes three viral proteins on overlapping reading frames: VP1, the 52 kDa structural capsid protein; VP3, a 13·8 kDa virulence factor known to induce apoptosis in transformed cell lines; and VP2, a 28 kDa dual-specificity protein phosphatase (DSP) (Peters et al., 2002). The signature motif for the serine, threonine and tyrosine phosphatase activity has been identified in VP2 and key catalytic residues have been identified by expression and mutagenesis studies.
Mutagenesis of either of the cysteine residues to serines at positions 95 and 97 within the catalytic motif of VP2 markedly reduced virus replication in cell culture (Peters et al., 2002). This suggests that VP2 protein phosphatase activity is not essential, but is required for efficient replication. The definition of a precise biochemical function for CAV VP2 as a DSP greatly facilitates the design of a mutagenesis strategy and provides a rational basis for the generation of mutants with altered VP2 function. However, it is likely that CAV VP2 is a multifunctional protein with a non-structural role in virus infection and replication. Expression studies by Noteborn et al. (1998) have shown that co-expression of both VP1 and VP2 was required for the generation of recombinant proteins capable of inducing neutralizing antibodies. Thus, VP2 may also have a role as a scaffolding protein during virion assembly and hence the effect of VP2 mutations that alter protein secondary structure could be to slow virus assembly.
The objective of this study was to examine the role of VP2 in viral cytopathogenicity and its influence on growth characteristics of the virus. Our previous studies of viruses with mutations affecting the two cysteine residues at the DSP catalytic site found that these mutations resulted in a marked reduction in replication efficiency and infectivity. Thus, sites that might be expected to only subtly modify DSP activity or to maintain DSP activity were targeted.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). The entire genome of this infectious clone has been sequenced and the sequence submitted to GenBank (accession no. AF227982). Sites were targeted for mutagenesis on the basis of VP2 functional analysis (Peters et al., 2002, 2005) and protein structural analysis. The key residues C87, R101, K102 and H103 were identified within the protein loop associated with the DSP signature motif by comparison with known protein tyrosine phosphatase (PTPase) structures (Peters et al., 2002, 2005) (Fig. 1). Residues were also targeted within a region of VP2 predicted to have a high degree of secondary structure. VP2 protein structural predictions were made using software available through the Australian National Genomic Information Service interface. Protein modelling was used to derive tertiary structural predictions using the Swiss Pdb Viewer software available through the EXPASY (Expert Protein Analysis System) server of the Swiss Institute for Bioinformatics (www.expasy.ch/spdbv). Residues targeted for mutagenesis on the basis of structural analysis of VP2 were R129, R/K/K150/151/152, Q131, L163, D/E161/162, D169 and E186 (Fig. 1).
|
). For each mutation introduced, paired overlapping oligonucleotides, complementary to both strands of the VP2 gene sequence, were synthesized (Table 1). The oligonucleotide pairs were designed to incorporate nucleotide substitutions encoding the amino acid alterations. The regions of the VP2 gene targeted for mutagenesis overlapped the VP3 and VP1 genes, which are frame-shifted relative to VP2 by one and two bases, respectively, but none of the mutations introduced changed the sequences of VP3 or VP1.
|
The upstream flanking primer CAV.5, 5'-GCGGAGCCGCGCAGGGGCAA-3', and downstream flanking primer CAV.4, 5'-TGCTCACGTATGTCAGGTTC-3', were used for the construction of R101G, R129G, Q131P, R/K/K150/151/152G/A/A, D/E161/162G/G, L163P, D169G and E186G. In the first stage, the reaction was incubated at 95 °C for 2 min, followed by 30 cycles of 95 °C for 40 s, 60 °C for 60 s and 68 °C for 40 s, with a final incubation at 68 °C for 5 min. The first-stage template was removed by digestion with DpnI (Boehringer Mannheim) and the stage-one products were purified by gel electrophoresis and Qiaex II (Qiagen) gel extraction according to the manufacturer's instructions. The second-stage PCR was incubated at 96 °C for 2 min, followed by 15 cycles of 96 °C for 40 s, 58 °C for 60 s and 72 °C for 60 s, with a final incubation at 72 °C for 5 min.
The PCR products were digested with StuI and BsmI (both from New England Biolabs) and purified by gel electrophoresis as above. The plasmid pCAU269/7 was also digested with StuI and BsmI to remove the region of 357 bp to be replaced with the mutated sequence and the remainder of the plasmid was purified by gel electrophoresis. The PCR product was then ligated to the plasmid. Escherichia coli strain DH5
was electrotransformed with the ligated plasmid and transformants were selected by culture at 37 °C on Luria–Bertani agar containing 50 µg ampicillin ml–1 (Sambrook et al., 1989). Clones were screened for the presence of the insert by PCR using the forward primer CAV.5 and reverse primer CAV.4 in a 100 µl reaction mixture containing 300 µM each of dATP, dCTP, dGTP and dTTP, 2 mM MgCl2, 0·2 µM of each primer, 10 µl 10x Taq DNA polymerase buffer (Promega), 2 U Taq DNA polymerase (Promega) and 2 µl template DNA. The reaction was incubated at 96 °C for 2 min, followed by 40 cycles of 96 °C for 40 s, 63 °C for 60 s and 72 °C for 60 s, and a final incubation at 72 °C for 5 min. The cloned DNA was sequenced using a Taq DyeDeoxy Terminator cycle sequencing kit (Perkin Elmer) and primers CAV.5 and CAV.4.
The construction of K102D was as described for R101G, R129G, Q131P, R/K/K150/151/152G/A/A, D/E161/162G/G, L163P, D169G and E186G but, following mutagenesis, the PCR product was cloned initially into the pGEM-4T-2 vector (Promega), the plasmid DNA was digested with StuI and BsmI and the CAV gene fragment was subcloned into the digested pCAU269/7.
Mutations C87R and H103Y were generated by full-circle, overlap extension mutagenesis in a single PCR. The reaction mixture was as described above, except that only the relevant mutagenesis primers were included. The reaction was incubated at 96 °C for 2 min, followed by 1 cycle of 96 °C for 40 s, 55 °C for 60 s and 68 °C for 5 min, then 40 cycles of 96 °C for 40 s, 60 °C for 60 s and 68 °C for 5 min, with a final incubation at 68 °C for 5 min. Template DNA was removed by digestion with DpnI and the PCR product was purified by phenol/chloroform/isoamyl alcohol (25 : 24 : 1, by volume) extraction and ethanol precipitation. The PCR product containing C87R and pCAU269/7 were digested with ApaI (New England Biolabs) and StuI rather than BsmI and StuI. Cloning for both C87R and H103Y was otherwise as described for R101G, R129G, Q131P, R/K/K150/151/152G/A/A, D/E161/162G/G, L163P, D169G and E186G.
Transfection of mutated viral genomes into MDCC-MSB1 cells.
Transfection of MDCC-MSB1 cells with viral genome was used to generate mutant virus from genomic DNA that had been mutagenized in vitro. Plasmid DNA was digested with EcoRI (New England Biolabs) to release the CAV genome, which was purified by gel electrophoresis and extraction and resuspended in sterile 10 mM Tris (pH 8·0).
MDCC-MSB1 cells were washed twice in RPMI 1640 medium (Sigma–Aldrich), resuspended at a final concentration of 107 cells ml–1 and 700 µl was added to 10 µg DNA in a microfuge tube on ice. Transfection was performed in a 0·4 cm gap electroporation cuvette in a Gene Pulser apparatus (Bio-Rad) set at 400 V, 900 µF, 
resistance and extension capacitance. The cells were incubated at room temperature for 5 min, then resuspended in 5 ml warm growth medium. The cells were grown as suspension cultures at 37 °C in 5 % CO2 in RPMI 1640 medium supplemented with 2 mM glutamine (Sigma–Aldrich), 2 mM pyruvate (Sigma–Aldrich), 0·2 % NaHCO3, 50 µg ampicillin ml–1, 50 µg gentamicin (Sigma–Aldrich) ml–1 and 10 % fetal calf serum (CSL).
Mutant virus propagation.
Transfected cell cultures were serially passaged at a 1/10 dilution at 48 h intervals for ten passages. Infectivity was assessed every 48 h by examining the proportion of cells expressing CAV VP3 by indirect immunofluorescence staining (IFA) with mouse anti-VP3 monoclonal antibody (mAbVP3; Tropbio) diluted 1/200 in 0·1 % BSA/PBS/0·5 % Tween 20 (BSA/PBST) and secondary sheep anti-mouse antibody conjugated to fluorescein isothiocyanate (FITC; Dako) diluted 1/100 in 0·1 % BSA/PBST. The presence of infectious mutant virus was further demonstrated by reinfection of cell cultures with cell-free preparations from the earliest passages of transfected cultures that had at least 50 % of cells infected with CAV as determined by IFA. The culture was frozen and thawed three times and then clarified by centrifugation at 6000 g for 10 min. MDCC-MSB1 cells were then infected with the cell-free virus preparation. These infected cultures were assessed by IFA for VP3 expression. Western blotting of cell lysates using mAbVP3 was also used to confirm infectivity of mutated viruses.
DNA for CAV-specific PCR was purified from MDCC-MSB1 cells 48 h after infection using proteinase K and SDS lysis (Meehan et al., 1992) and phenol/chloroform extraction (Sambrook et al., 1989). The extracted DNA was digested with DpnI to remove any residual transfected DNA. The mutated region was then amplified using the CAV.5 and CAV.4 primers and the PCR conditions described above for screening clones for the presence of insert by PCR. The mutant genotypes were confirmed by sequencing of the PCR product.
Mutant viruses were titrated in 96-well trays in 200 µl volumes containing 5x105 MDCC-MSB1 cells ml–1 using an adaptation of a method published previously by Goryo et al. (1987). Six duplicate tenfold dilution series of viral stocks were prepared, ranging from a final dilution of 0·05 to 0·5x10–10, and inoculated onto cells. At intervals of 48 h, cells were passaged into fresh medium at a dilution of 1 : 4. Each well was scored for evidence of cytopathogenic effect (CPE) and cultures were serially passaged until no difference was detected between successive passages at the lowest dilution at which CPE was observed. The observation of CPE was confirmed by IFA with mAbVP3 of the end-point dilution.
One-step growth curves of mutant viruses.
One-step growth curves were determined for all mutant viruses by infecting 106 cells at an m.o.i. of one (Flint et al., 2000). Samples of infected cell cultures were taken at 4 h intervals over a 60 h period commencing 8 h after infection. Pelleted cells and supernatant from each time point were individually titrated with six repetitions. Pelleted cells were lysed by three cycles of freeze–thawing and clarified prior to titration. The eclipse period (defined as the period between inoculation and the last time point sampled at which virus was not detectable extracellularly or intracellularly) and the latent period (defined as the time between inoculation and the last time point before extracellular virus was detected) were determined.
Cytology.
In vitro cytopathology was assessed by phase-contrast microscopy of viable cultures and by IFA of fixed cells with mAbVP3 and counterstaining for 2 min with Höescht stain.
Infected cells were stained 24 h after infection in separate reactions with mouse anti-chicken CD8 mAb–FITC conjugate and mouse anti-chicken CD4 mAb–FITC conjugate (both Southern Biotechnology) and then with mouse anti-chicken major histocompatibility complex (MHC) I mAb–phycoerythrin (PE) conjugate (Southern Biotechnology), all diluted 1/100 in 0·1 % BSA/PBST with incubation for 1 h for each staining reaction. The sensitivity and specificity of the MHC class I monoclonal antibody was determined using a dilution series of the antibody to stain MDCC-MSB1 cells. The dilution of antibody used in the study was the highest at which there was no reduction in the number of positive cells identified. The proportion of the cells stained for CD8 that were also stained for MHC I was determined using a flow cytometer (Facscalibur; Becton Dickinson). Data were analysed using Cellquest software (Becton Dickinson). Sample populations of 108 cells were recorded on density plots, with the intensity of FITC staining on the x axis and the intensity of PE staining on the y axis. Quadrants established from plots of control cells were used to delineate positively and negatively stained populations.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
A region with a high degree of secondary structure was predicted towards the carboxyl-terminal end of VP2. Chou–Fasman plots of the region predicted an acidic region of -helix, followed by a basic region of -helix and 
-sheet, and a second acidic region of -helix. The secondary structure was subdivided by a series of proline residues. There were three predicted regions of amphipathic -helix from residues 128 to 143, 160 to 171 and 174 to 187 and amphipathic -sheet from residues 151 to 158. These secondary structure predictions were in agreement with those obtained using the Garnier, Osguthorpe and Robson algorithms. We predicted that the high degree of secondary structure correlated with a functional protein domain and mutations were designed to disrupt the structural organization of the region, thereby modifying any potential function. It is also possible that the predicted amphipathic helices may contribute to the properties of the protein phosphatase catalytic cleft and thereby to the activity of the enzyme.
The three-dimensional model obtained by threading VP2 onto mouse protein tyrosine phosphatase A (muPTPA) predicted an internal domain consisting of five -strands, which would form the catalytic cleft of the protein. In both the muPTPA and VP2 models, this region had a concentration of basic residues aligned along the axis of the -sheet. Flanking each side of the cleft are regions of -helix. The two -helices flanking the cleft towards the carboxyl terminus in VP2 were predicted to be acidic-faced, amphipathic helices. They formed a continuous face of negative charge across the surface of the protein. This acidic charge distribution was not found in the corresponding domain of the muPTPA model. The -helix towards the amino side of the cleft was predicted by the Chou–Fasman algorithm to be positioned between residues 51 and 60, rather than between residues 71 and 76, as predicted by the threaded model. When the -helix was positioned between residues 51 and 60 in the threaded model, the effect was to slightly raise the elevation of the first helix above the catalytic cleft and the loop of random coil that corresponds to the WPD loop of the muPTPA model was less exposed.
Within the region of predicted, basic amphipathic -helix, R129G and R/K/K150/151/152G/A/A were constructed to neutralize the polar basic charge distribution in the secondary structure. The substitution Q131P was also introduced into the -helix in this region to break the helix. An identical approach involved the introduction of L163P into a segment of basic -strand to disrupt the conformation. The introduction of proline at positions 131 and 163 was predicted, using the GROMOS96 43BI parameter set, to increase the energy at both locations by 100-fold. These mutations would be expected to destabilize the secondary structure. The substitutions D/E161/162G/G, D169G and E186G were introduced with the objective of neutralizing the acidic charge distribution in the amphipathic helices.
Transfection of mutated viral genomes into MDCC-MSB1 cells
Four to five serial passages were required for wild-type virus at tenfold dilutions before an exponential increase was seen in the numbers of cells stained for VP3 expression by IFA, which was interpreted as active virus replication and infection rather than simply maintenance of transfected DNA constructs. The number of passages required to reach this point varied, but was in the range of five to eight passages for all mutated genomes. Mutant virus was harvested from the earliest passage at which an exponential increase in VP3 expression was observed.
Replication competency and titre of mutant viruses
Cell-free virus generated from each mutated genome was able to infect fresh cell cultures, as confirmed by IFA and Western blotting to detect VP3 and by CAV-specific PCR. Although replication-competent virus was generated from all mutant constructs, mutant virus Mut K102D produced maximal titres of only 101·5 TCID50 ml–1, despite repeated attempts to optimize the culture conditions. These titres were considered too low for propagation and further assessment of growth. For viruses Mut C87R, Mut R101G, Mut H103Y, Mut R129G, Mut Q131P, Mut R/K/K150/151/152G/A/A, Mut D/E161/162G/G, Mut L163P, Mut D169G and Mut E186G, initial titres were in the range 103–104 TCID50 ml–1. For these viruses, 400 ml infected culture was concentrated by ultracentrifugation and resuspended at 104·5 TCID50 ml–1.
One-step growth curves
One-step growth curves were determined for all viruses (Table 2). The eclipse and latent periods for wild-type CAU269/7 were found to be 24 h. The burst size for the wild-type CAU269/7 virus was 106 TCID50 ml–1. Infectious virus was present in the supernatant 8 h before it was found intracellularly and the plateau titre for intracellular virus was tenfold higher than that for extracellular virus. The eclipse period for all mutant viruses tested was approximately 40 h, with the exception of Mut R/K/K150/151/152G/A/A, for which the eclipse and latent periods were 24 h, as for wild-type virus, and Mut E186G, for which the eclipse period was 28 h and the latent period only slightly longer at 32 h. For viruses Mut C87R, Mut H103Y and Mut D169G, the latent period was 40 h and infectious virus was detected in the supernatant before it was detected intracellularly. For viruses Mut R101G, Mut R129G, Mut Q131P, Mut D/E161/162G/G and Mut L163P, the latent period was in the range 44–60 h and the detection of extracellular infectious virus was delayed significantly, with virus initially being detected intracellularly. The burst size for viruses Mut H103Y, Mut Q131P, Mut D/E161/162G/G and Mut E186G was 106 TCID50 ml–1, equivalent to wild-type. The burst size for viruses Mut C87R, Mut R101G, Mut R129G, Mut R/K/K150/151/152G/A/A, Mut L163P and Mut D169G was 105 TCID50 ml–1, tenfold lower than for wild-type virus.
|
Viruses mutated in VP2 replicated in MDCC-MSB1 cells, but induced only mild CPE. MDCC-MSB1 cells infected with viruses Mut R/K/K150/151/152G/A/A and Mut L163P are shown in Fig. 2 as examples of the characteristic cytopathology. Mild cellular swelling, mild cytoplasmic vacuolation and mild nuclear pyknosis were evident. CPE was more obvious in MDCC-MSB1 cell cultures infected with viruses Mut R129G, Mut Q131P, Mut R/K/K150/151/152G/A/A, Mut L163P or Mut E186G than in those infected with viruses Mut C87R, Mut R101G, Mut K102D, Mut H103Y, Mut D/E161/162G/G or Mut D169G. MDCC-MSB1 cell cultures infected with viruses Mut R129G, Mut Q131P, Mut R/K/K150/151/152G/A/A or Mut L163P were examined by immunostaining for VP3. Nuclei of cells infected with these mutant viruses stained uniformly with Höescht stain, as in uninfected cells, and there was no evidence of nuclear fragmentation or chromatin clumping (Fig. 2). IFA for VP3 identified intensely stained, crescent-shaped aggregates of VP3 in the cytoplasm, but VP3 was not detected in the nucleus (Fig. 2).
|
and Table 3). Following CAU269/7 infection, the shape of the distribution changed markedly. A larger proportion of cells had lower levels of cell-surface expression of MHC class I and the geometric mean and median of the distribution were reduced (Table 3). The shape of the distributions and geometric means for MHC class I–PE staining intensity on cells infected with Mut R101G or Mut H103Y resembled the distribution for uninfected MDCC-MSB1 cells (Fig. 3). For cells infected with Mut Q131P, the shape of the distribution was intermediate between those of wild-type-infected and uninfected cells (Fig. 3). For this virus, there was a slight shift in the geometric mean to the left and a shoulder to the distribution, indicating a small proportion of cells with lower levels of surface expression of MHC class I.
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
, 1999, 2000). In our study, site-directed mutagenesis of VP2, based on a carefully designed strategy, was found to be an effective means of rapidly generating viruses with distinct phenotypes.
The sites for mutagenesis were selected based on predictions of the protein secondary structure. The secondary structure predictions for VP2 were compared with a three-dimensional model of VP2 obtained by threading the VP2 sequence onto the solved muPTPA crystallographic structure. In general, there was a high degree of agreement between the structural predictions based on amino acid sequence alone and the model based on the muPTPA crystallographic structure, with the exception of the regions from residues 99 to 109 and from residues 116 to 123, which were predicted to be -helix using the Chou–Fasman algorithm and to be -strand in the threaded model. The threading energy computed using the GROMOS96 43BI parameter set (DF. Hochschulverlag ETHZ; http://igc.ethz.ch/gromos) for residues 99–109 and 116–123 of the VP2 model was highly favourable for a -strand conformation. On this basis, predictions of either -helical or -strand conformations would be equally energetically feasible for this region.
In general, DNA viruses require entry into the nucleus for replication to commence and therefore they tend to have longer latent periods than viruses replicating in the cytoplasm. CAV was found to have a lengthy latent period, as is found for other DNA viruses. Simple viruses such as CAV may require the host cell to enter the S phase of the cell cycle for the cell to be permissive for virus replication. As the number of actively dividing cells at the time of infection may influence the latent period, the cells were passaged 24 h prior to infection. We found that, for wild-type infection of MDCC-MSB1 cells, infectious virus was detected in the extracellular supernatant prior to intracellular virus, but that, ultimately, virus in the intracellular fraction was of higher titre than virus in the extracellular fraction. For many viruses, modifications to the virus capsid or envelope at the point of release from the cell confer infectivity on the virus particle and, for these viruses, infectious virus is found first in the supernatant. No such modifications have been identified for the CAV particle and this is unlikely to be a factor in CAV infectivity, as infectious virus is also found intracellularly at a later stage after infection. It is possible that infectious virus was present first in the supernatant because virus assembly and release coincide temporally with host-cell lysis.
Mutation of the VP2 gene conferred distinct growth characteristics on all viruses tested. All mutants could be grouped into one of three different types of growth curve, the first being the wild-type pattern. Virus Mut R/K/K150/151/152G/A/A had a growth curve similar to that of wild-type virus. The second cluster of viruses, Mut C87R, Mut H103Y, Mut D169G and Mut E186G, had eclipse and latent periods that were prolonged by about the same amount relative to wild-type. As for infection with wild-type virus, infectious virus was first detected extracellularly. The prolonged eclipse period may reflect greater reliance on active cell division than for wild-type virus. For the third cluster of viruses, Mut R101G, Mut R129G, Mut Q131P, Mut D/E161/162G/G and Mut L163P, the eclipse period was prolonged by an amount similar to most other mutants, but the latent period was much more prolonged. For these viruses, infectious virus was first detected intracellularly, rather than extracellularly. The long latent period and the significant interval between infectious virus being found intracellularly and being released into the supernatant may reflect a reduced capacity for assembly and release of virions. The burst size for wild-type CAU269/7 and for viruses Mut H103Y, Mut Q131P and Mut D/E161/162G/G was 106 TCID50 ml–1.
Therefore, it could be expected that these viruses could be grown to titres equivalent to wild-type under appropriate culture conditions. For viruses Mut C87R, Mut R101G, Mut R129G, Mut R/K/K150/151/152G/A/A, Mut L163P and Mut D169G, burst size was approximately tenfold lower than that for wild-type.
Virus Mut K102D grew in cell culture following transfection. However, reinfection with cell-free virus resulted in only very low levels of infectivity, even with repeated passaging, suggesting that the mutation resulted in inefficient virus replication and infectivity, as seen for viruses containing the C95S and C97S mutations (Peters et al., 2002, 2005). Both the C95S and C97S mutations are known to either reduce or abrogate VP2 PTPase activity in vitro (Peters et al., 2002, 2005). Interestingly, there are two basic residues within the signature motif CXCXXXRK of CAV VP2 DSP, at positions R101 and K102. As the mutation R101G does not significantly affect replication efficiency, it seems likely that it might not induce a reduction in DSP activity. Alternatively, it might be postulated that the attenuation observed for the R101G mutation may involve modification of only the serine/threonine protein phosphatase (S/T PPase) activity of the DSP, which does not appear to be linked as closely to reduced replication efficiency because, even though the C95S mutation abrogates S/T PPase activity and the C97S mutation enhances this activity, viruses with either of these mutations have marked reductions in replication efficiency (Peters et al., 2002, 2005).
VP3 alone can induce apoptosis in transformed cell lines, but not in normal cells. VP3 is rapidly compartmentalized into the nucleus of transformed cells, whereas it remains localized in the cytoplasm of untransformed cells (Danen-Van Oorschot et al., 1997). Deletion of the nuclear transport signals in VP3 blocks its capacity to induce apoptosis in transformed cells. Nuclear transport of VP3 in transformed cell lines is dependent on phosphorylation of threonine 108. During infection with VP2 mutants, VP3 was distributed only in the cytoplasm and, in some cases, in focal cytoplasmic aggregates or granules, parallelling the difference observed between transformed and normal cells (Noteborn, 2004). It is possible that VP2 mutations alter the trafficking of VP3 into the nucleus that normally occurs in transformed cell lines. Thus, VP2 may regulate the phosphorylation state of VP3 and therefore the induction of apoptosis in a cell. As virus replication occurs within the nucleus, it is possible that compartmentalization of VP3 in the cytoplasm may result in prolongation of the latent period.
Downregulation of MHC class I cell-surface expression was found in CD8+ MDCC-MSB1 cells after infection with CAU269/7. MHC class I expression is typically upregulated in an adaptive antiviral response (Joyce, 2001). Although MDCC-MSB1 cells are functionally and phenotypically distinct from untransformed lymphocytes in vivo, the virus-specific downregulation of MHC class I suggests an interaction with host-cell messenger pathways that may also occur in untransformed lymphocytes and is thus a potential viral mechanism for suppression of cytotoxic lymphocyte responses.
VP2 mutations R101G and H103Y significantly abrogated the virally induced downregulation of MHC class I and mutation Q131P partially abrogated the effect. This confirmed that MHC class I downregulation was a virus-specific effect and suggests that VP2 is a mediator of MHC class I downregulation. The substitutions R101G and H103Y had a predicted location in the peptide loop containing the DSP signature motif, whereas substitution Q131P had a predicted location in a segment of -helix adjacent to the catalytic cleft. As many protein phosphatases have interactions with lymphocyte signalling pathways, it is possible that VP2 DSP activity may have been a mediator of the MHC class I downregulation.
Mutations introduced into the region of VP2 predicted to have a high degree of secondary structure either neutralized acidic or basic charged residues or introduced prolines into a sequence that was predicted to form an -helix. Although functional roles for this region are unknown, it was hypothesized that a high degree of secondary structure would correlate with a functional role. Subtle alterations to conformation may potentially change affinities or specificities for binding with other proteins. Although the effect of these mutations on VP2 function is not known, the phenotypic effect, both in CPE and growth characteristics, suggests a structure–function relationship. The differences in growth characteristics between these viruses suggests that the mutations had different effects on VP2 function.
Thus, the studies reported here have identified a previously unrecognized effect of CAV on lymphocytic cells and have also demonstrated the effect of mutations in VP2 on replication, CPE and MHC class I downregulation in a lymphocytic cell line.
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Bisgaard, M. (1983). An age related and breeder flock associated haemorrhagic disorder in Danish broilers. Nord Vet Med 35, 397–407.[Medline]
Brown, H. K., Browning, G. F., Scott, P. C. & Crabb, B. S. (2000). Full-length infectious clone of a pathogenic Australian isolate of chicken anaemia virus. Aust Vet J 78, 637–640.[Medline]
Caterina, K. M., Frasca, S., Jr, Girshick, T. & Khan, M. I. (2004). Development of a multiplex PCR for detection of avian adenovirus, avian reovirus, infectious bursal disease virus, and chicken anemia virus. Mol Cell Probes 18, 293–298.[Medline]
Chettle, N. J., Eddy, R. K., Wyeth, P. J. & Lister, S. A. (1988). An outbreak of disease due to chicken anemia agent in broiler chickens in England. Vet Rec 124, 211–215.
Danen-Van Oorschot, A. A., Fischer, D. F., Grimbergen, J. M. & 7 other authors (1997). Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci U S A 94, 5843–5847.
Danen-Van Oorschot, A. A., van der Eb, A. J. & Noteborn, M. H. (1999). BCL-2 stimulates apoptin-induced apoptosis. Adv Exp Med Biol 457, 245–249.[Medline]
Danen-van Oorschot, A. A., van der Eb, A. J. & Noteborn, M. H. (2000). The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol 74, 7072–7078.
Engstrom, B. E., Fossum, O. & Luthman, M. (1988). Blue wing disease of chickens: experimental infection with a Swedish isolate of chicken anaemic agent and avian reovirus. Avian Pathol 17, 33–50.
Fadley, A. M., Motta, J. V., Witter, R. L. & Nordgren, R. M. (1994). Epidemiology of chicken anaemia virus in specific-pathogen-free chicken breeder flocks. In International Symposium on Infectious Bursal Disease and Chicken Infectious Anaemia, pp. 447–455. Rauischholzhausen, Germany.
Farkas, T., Tanaka, A., Kai, K. & Kanoe, M. (1996). Cloning and sequencing of the genome of chicken anaemia virus (CAV) TK-5803 strain and comparison with other CAV strains. J Vet Med Sci 58, 681–684.[Medline]
Flint, S. J., Enquist, L. W., Krug, R. M., Racaniello, V. R. & Skalka, A. M. (2000). Principles of Virology: Molecular Biology, Pathogenesis and Control, pp. 25–56. Washington, DC: American Society for Microbiology.
Goryo, M., Suwa, T., Matsumoto, S., Umemura, T. & Itakura, C. (1987). Serial propagation and purification of chicken anaemia agent in MDCC-MSB1 cell line. Avian Pathol 16, 149–163.[Medline]
Joyce, S. (2001). Immune recognition, response, and regulation: how T lymphocytes do it. Immunol Res 23, 215–228.[Medline]
Markowski-Grimsrud, C. J. & Schat, K. A. (2003). Infection with chicken anaemia virus impairs the generation of pathogen-specific cytotoxic T lymphocytes. Immunology 109, 283–294.[CrossRef][Medline]
McIlroy, S. G., McNulty, M. S., Bruce, D. W., Smyth, J. A., Goodall, E. A. & Alcorn, M. J. (1992). Economic effects of clinical chicken anemia agent infection on profitable broiler production. Avian Dis 36, 566–574.[Medline]
McNulty, M. S. (1997). Gordon Memorial Lecture. Chicken anaemia virus – a glimpse of the future? Br Poult Sci 38, 7–13.[Medline]
McNulty, M. S., Connor, T. J., McNeilly, F., Kirkpatrick, K. S. & McFerran, J. B. (1988). A serological survey of domestic poultry in the United Kingdom for antibody to chicken anaemia agent. Avian Pathol 17, 315–324.[Medline]
McNulty, M. S., Connor, T. J., McNeilly, F. & Spackman, D. (1989). Chicken anemia agent in the United States: isolation of the virus and detection of antibody in broiler breeder flocks. Avian Dis 33, 691–694.[CrossRef][Medline]
Meehan, B. M., Todd, D., Creelan, J. L., Earle, J. A., Hoey, E. M. & McNulty, M. S. (1992). Characterization of viral DNAs from cells infected with chicken anaemia agent: sequence analysis of the cloned replicative form and transfection capabilities of cloned genome fragments. Arch Virol 124, 301–319.[CrossRef][Medline]
Miller, M. M. & Schat, K. A. (2004). Chicken infectious anemia virus: an example of the ultimate host-parasite relationship. Avian Dis 48, 734–745.[Medline]
Noteborn, M. H. (2004). Chicken anemia virus induced apoptosis: underlying molecular mechanisms. Vet Microbiol 98, 89–94.[Medline]
Noteborn, M. H. M., Verschueren, C. A. J., Koch, G. & Van der Eb, A. J. (1998). Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope. J Gen Virol 79, 3073–3077.[Abstract]
Peters, M. A., Jackson, D. C., Crabb, B. S. & Browning, G. F. (2002). Chicken anemia virus VP2 is a novel dual specificity protein phosphatase. J Biol Chem 277, 39566–39573.
Peters, M. A., Jackson, D. C., Crabb, B. S. & Browning, G. F. (2005). Mutation of chicken anemia virus VP2 differentially affects serine/threonine and tyrosine protein phosphatase activities. J Gen Virol 86, 623–630.
Pringle, C. R. (1999). Virus Taxonomy at the XIth International Congress of Virology, Sydney, Australia, 1999. Arch Virol 144, 2065–2070.[CrossRef][Medline]
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Commonly used techniques in molecular cloning. In Molecular Cloning: a Laboratory Manual, 2nd edn, pp. E3–E4. Edited by C. Nolan. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
Sommer, F. & Cardona, C. (2003). Chicken anemia virus in broilers: dynamics of the infection in two commercial broiler flocks. Avian Dis 47, 1466–1473.[Medline]
Vielitz, E. & Landgraf, H. (1988). Anaemia-dermatitis of broilers: field observations of its occurrence, transmission and prevention. Avian Pathol 17, 113–120.[Medline]
von Bulow, V. & Lesjak, M. (1987). Modified ELISA for the detection of antiviral antibodies in chicken sera including the use of virus-free cellular antigens for specificity control. Zentralbl Veterinarmed B 34, 655–669 (in German).[Medline]
Yuasa, N. (1983). Propagation and infectivity titration of the Gifu-1 strain of chicken anemia agent in a cell line (MDCC-MSB1) derived from Marek's disease lymphoma. Natl Inst Anim Health Q (Tokyo) 23, 13–20.[Medline]
Yuasa, N., Taniguchi, T., Imada, T. & Hihara, H. (1983). Distribution of chicken anemia agent (CAA) and detection of neutralizing antibody in chicks experimentally inoculated with CAA. Natl Inst Anim Health Q (Tokyo) 23, 78–81.[Medline]
Received 29 August 2005;
accepted 14 December 2005.
This article has been cited by other articles:
|
|
 |
|
  M. A. Peters, B. S. Crabb, K. A. Tivendale, and G. F. Browning Attenuation of chicken anemia virus by site-directed mutagenesis of VP2 J. Gen. Virol., August 1, 2007; 88(8): 2168 - 2175. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
